ReviewJournal of viral hepatitis2013
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
Review in Journal of viral hepatitis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02707991 (Nurse Case Management to Improve Linkage to Hepatitis C Care and Treatment Initiation in HIV Co-infection), which is not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nurse Case Management to Improve Linkage to Hepatitis C Care and Treatment Initiation in HIV Co-infection: A Randomized Controlled Trial
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape.Liver international : official journal of the International Association for the Study of the Liver · 2016Guideline
- Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.Annals of internal medicine · 2017Trial
- Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.AIDS (London, England) · 2016Trial
- Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.Addiction (Abingdon, England) · 2015Trial
- Resource Management through Artificial Intelligence in Screening Programs-Key for the Successful Elimination of Hepatitis C.Diagnostics (Basel, Switzerland) · 2022Article
- Prevalence of Hepatitis C Virus Infection Identified From Nontargeted Screening Among Adult Visitors in an Academic Appalachian Regional Emergency Department.Open forum infectious diseases · 2021Article
- Patients at a drug detoxification center share perspectives on how to increase hepatitis C treatment uptake: A qualitative study.Drug and alcohol dependence · 2021Article
- Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Community Screening, Identification, and Referral to Primary Care, for Hepatitis C, B, and HIV Among Homeless Persons in Los Angeles.Journal of community health · 2019Article
- Increasing hepatitis C screening in a large integrated health system: science and policy in concert.The American journal of managed care · 2018Observational
- Article
- 'Sussing that doctor out.' Experiences and perspectives of people affected by hepatitis C regarding engagement with private general practitioners in South Australia: a qualitative study.BMC family practice · 2017Article
- Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C.Israel journal of health policy research · 2017Article
- Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?Frontiers in pharmacology · 2017Article
- Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.Journal of clinical and translational hepatology · 2016Review
- Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections.World journal of hepatology · 2016Review
- Characterizing Failure to Establish Hepatitis C Care of Baby Boomers Diagnosed in the Emergency Department.Open forum infectious diseases · 2016Article
- Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States.Journal of clinical and translational hepatology · 2016Article
- The Hepatitis C virus treatment cascade at an urban postincarceration transitions clinic.Journal of viral hepatitis · 2016Article
- High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 15 institutions in 3 countries.
Funding
Abstract
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter in duration and simpler to administer. Coinciding with new treatment options are novel methodologies for disease screening and staging, which create the possibility of more timely care and treatment. Assessments of histologic damage typically are performed using liver biopsy, yet noninvasive assessments of histologic damage have become the norm in some European countries and are becoming more widespread in the United States. Also in place are new Centers for Disease Control and Prevention (CDC) initiatives to simplify testing, improve provider and patient awareness and expand recommendations for HCV screening beyond risk-based strategies. Issued in 2012, the CDC recommendations aim to increase HCV testing among those with the greatest HCV burden in the United States by recommending one-time testing for all persons born during 1945-1965. In 2013, the United States Preventive Services Task Force adopted similar recommendations for risk-based and birth-cohort-based testing. Taken together, the developments in screening, diagnosis and treatment will likely increase demand for therapy and stimulate a shift in delivery of care related to chronic HCV, with increased involvement of primary care and infectious disease specialists. Yet even in this new era of therapy, barriers to curing patients of HCV will exist. Overcoming such barriers will require novel, integrative strategies and investment of resources at local, regional and national levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.